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Background: The bisdioxopiperazine dexrazoxane (DRZ) prevents anthracycline-induced heart failure, but its clinical
use is limited by uncertain cardioprotective mechanism and by concerns of interference with cancer response to
anthracyclines and of long-term safety.
Methods: We investigated the effects of DRZ on the stability of topoisomerases IIα (TOP2A) and IIβ (TOP2B) and on
the DNA damage generated by poisoning these enzymes by the anthracycline doxorubicin (DOX).
Results: DRZ given i.p. transiently depleted in mice the predominant cardiac isoform Top2b. The depletion was also
seen in H9C2 cardiomyocytes and it was attenuated by mutating the bisdioxopiperazine binding site of TOP2B.
Consistently, the accumulation of DOX-induced DNA double strand breaks (DSB) by wild-type, although not by mutant
TOP2B, was reduced by DRZ. In contrast, the DRZ analogue ICRF-161, which is capable of iron chelation but not of
TOP2B binding and cardiac protection, did not deplete TOP2B and did not prevent the accumulation of DOX-induced
DSB. TOP2A, re-expressed in cultured cardiomyocytes by fresh serum, was depleted by DRZ along with TOP2B. DRZ
depleted TOP2A also from fibrosarcoma-derived cells, but not from lung cancer-derived and human embryo-derived
cells. DRZ-mediated TOP2A depletion reduced the accumulation of DOX-induced DSB.
Conclusions: Taken together, our data support a model of anthracycline-induced heart failure caused by
TOP2B-mediated DSB and of its prevention by DRZ via TOP2B degradation rather than via iron chelation. The
depletion of TOP2B and TOP2A suggests an explanation for the reported DRZ interference with cancer response to
anthracyclines and for DRZ side-effects.Background
Heart failure (HF) is a foremost side-effect of oncological
therapies, most prominently those comprising anthracy-
clines, which are administered to an estimated 50% of
cancer patients. Certain reductions in heart failure rates
have been achieved by capping the maximal doses of
anthracyclines and by changing their administration
schedules. Nevertheless, heart failure continues to
affect up to 20% of anthracycline-treated patients [1].
The retrospectively identified individual risk factors
such as young or old age, female sex, cardiovascular co-
morbidities, certain co-therapies, and gene variants are* Correspondence: deng@uni-mainz.de
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unless otherwise stated.currently of limited help. This is due to the lack of pro-
spective clinical validation and to the scarcity of equipo-
tent anthracycline-free treatment alternatives. Particularly
problematic is the high HF risk in anthracycline-treated
children and in the elderly attributed, respectively, to the
long life expectancy and cardiac co-morbidities.
The bisdioxopiperazine dexrazoxane (DRZ, ICRF-
187) reduces the incidence of anthracycline-induced
heart failure by 80% and is the only drug approved for
its prevention [2]. Despite its impressive clinical effect,
DRZ is indicated only in patients with metastatic (in
the EU also with advanced) breast cancer who have
already received 300 mg/m2 doxorubicin (in the EU also
epirubicin, 540 mg/m2). Anecdotal evidence indicates a
limited off-label use of DRZ in cancer patients with car-
diac co-morbidities. DRZ is currently not approved fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ownership and marketing history, the limited indication
and use of DRZ reflect the persisting concerns of interfer-
ence with antitumor efficacy of anthracyclines [3], of in-
duction of secondary malignancies, and of myelodysplastic
syndrome [4], although recent meta-analyses [5] do not
support these concerns. One study even reported pro-
longed, almost doubled, survival of doxorubicin (DOX) re-
sponders co-treated with DRZ [6].
The clinical acceptance of DRZ has also suffered from
the incomplete understanding of its pharmacology. The
cardioprotective effect of DRZ is usually attributed to
iron chelating by ADR-925, an EDTA-like product of
the enzymatic DRZ hydrolysis. This is consistent with the
hypothesis of heart failure arising from iron-dependent
oxidative stress triggered by “redox cycling” of anthra-
cyclines. However, ADR-925 applied directly does not
protect cardiomyocytes against anthracyclines [7]. Con-
versely, the inhibition of the enzymatic DRZ conversion
to ADR-925 does not abolish the cardioprotective effect
[8]. Furthermore, cardioprotective activities of DRZ an-
alogues are unrelated to the rates of formation of their
iron-chelating (i.e. ADR-925-like) metabolites [9]. Finally,
the oxidative stress theory of anthracycline cardiotoxicity
has been questioned, since oxidative stress is detectable in
the heart following supra-clinical, but not clinically-
relevant anthracycline doses [10]. Accordingly, neither an-
tioxidants [11] nor iron chelators other than DRZ [12,13]
prevent anthracycline-induced HF in cancer patients.
On the other hand, several investigators have observed
depletion of the anthracycline target topoisomerase IIβ
(TOP2B) in cells treated with DRZ or its analogues
[14-16]. Lyu et al. [15] reported that DRZ-induced Top2b
depletion prevented anthracycline-induced DNA dam-
age in cardiomyocyte-derived H9C2 cells. Based on
these observations, Lyu et al. proposed that DRZ pre-
vents anthracycline-induced cardiomyocyte damage via
TOP2B depletion. Importantly, this model also implicates
that the anthracycline-induced cardiotoxicity is primarily
driven by TOP2B-mediated DNA damage. In support of
these findings, a recent study in cardiomyocyte-specific
knockouts suggested the involvement of Top2b in DOX-
induced cardiotoxicity [17]. Importantly, Top2b deletion
prevented DOX-driven mitochondrial damage, implicating
this enzyme as a common denominator of the mitochon-
drial and DNA damage-based models of anthracycline
cardiotoxicity.
The TOP2B-centered model of anthracycline-induced
heart failure and its prevention by DRZ clearly needs fur-
ther verification when weighed against the body of litera-
ture supporting the original oxidative stress hypothesis.
Furthermore, this model is incompatible with some other
findings. Thus, it is inexplicable why DRZ fully abolished
DOX-induced DNA double strand breaks (DSB) fromcultured cardiomyocytes, as DRZ left unchanged the ex-
pression level of the sister isoform Topoisomerase IIα
(TOP2A) [15], an established DOX target. The TOP2A
expression itself raises concerns regarding the validity of
the cells used as a cardiomyocyte model, as it is usually
expressed in proliferating and not post-mitotic cells [18].
On the other hand, DRZ has been recently reported to
deplete TOP2A from tumor cells [14]. This depletion
was proteasome-independent but it was associated with
a strong reduction of TOP2A mRNA, whereas TOP2B
mRNA remained unchanged. These results suggested
that DRZ may deplete both TOP2B and TOP2A via differ-
ent, transcriptional and proteolytic mechanisms, respect-
ively. The verification of this possibility is important not
only in organ protection but also for tumor treatments.
Indeed, tumor TOP2A expression is a strong predictor of
the therapeutic response to anthracyclines [19] and its re-
duction by DRZ could be deleterious. Therefore, we set
out to characterize the response of TOP2 isozymes to
DRZ in cardiac and tumor cells.Methods
Drugs and antibodies
DRZ was purchased from Chiron (Amsterdam, The
Netherlands), DOX was from Pfizer (Karlsruhe,
Germany). ICRF-161 and ICRF-193 were kindly pro-
vided by Dr. Annemette V. Thougaard (TopoTarget A/S,
Copenhagen, Denmark). The following antibodies were
used in Western blot: TOP2A/B (1: 200) and TOP2A
(1:2,000) from StressGen, TOP2B (1:2,000) from BD Phar-
mingen, γ-H2AX (1:500) from Abcam, GFP (1:5,000) from
Clontech, GAPDH (1:10,000) from Santa Cruz Biotech-
nology, α-tubulin (1:5,000) from Dianova (Germany) and
β-tubulin (1:100,000) from Sigma.Cell culture
HTETOP cells express TOP2A exclusively from a trans-
gene under the control of a tetracycline-repressive pro-
moter, have been previously established [20]. HTETOP
and the parental HT1080 cells were provided by Dr. An-
drew C.G. Porter (Centre for Haematology, Faculty of
Medicine, Imperial College London, England) and cul-
tured as previously described [14]. To obtain differenti-
ation, H9C2 cells (provided by Dr. Tomas Simunek,
Department of Biochemical Sciences, Charles University
in Prague, Czech Republic) were continuously cultured
for 14 days: 3 days in 10% FCS medium and the follow-
ing 11 days in 1% FCS medium. HEK293 cells were ob-
tained from Dr. Christian Mielke (Institute of Clinical
Chemistry and Laboratory Diagnostics, Heinrich-Heine-
University, Düsseldorf, Germany) and NYH cells were
from Dr. Annemette V. Thougaard (TopoTarget A/S,
Copenhagen, Denmark).
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Wild type C57BL/6 J (B6) mice were purchased from
Jackson Lab (Bar Harbor, ME) and they were 8–12
weeks old at the onset of experiment. Mice were injected
i.p. with 100 μl of saline (control group, n =3) or
200 mg/kg DRZ in the same volume of saline (DRZ
group, n =9). Animals were sacrificed by cervical dis-
location 6, 24 or 48 h after DRZ injection and the whole
hearts were isolated and snap-frozen in liquid nitrogen.
In parallel experiments, mice were injected with
200 mg/kg DRZ alone (n =3), 20 mg/kg DOX (n =3)
alone or in combination (n =3, DRZ was injected 30 min
before DOX). Heart tissues were removed 24 h later for
Western blot analysis. The mouse experiments described
in this paper have been permitted by the Animal Care
Committee of Rhineland-Palatinate (Koblenz, Germany)
with the permit No. AZ 23 177-07/G 12-1-043.
Western blot
Heart tissues from control or drug-treated mice were
homogenized thoroughly in RIPA buffer containing pro-
teinase inhibitors [14]. The lysate was subsequently incu-
bated for 2 h at 4°C with agitation. Cultured cells were
harvested and lysed in RIPA buffer followed by 30 min
incubation on ice. Twenty to 50 μg protein samples were
separated by SDS-PAGE as described previously [14].
Densitometric analysis of protein bands was performed
using the NIH Image J software.
RNA interfering and transient transfection
siRNA oligos were used to knock down human TOP2B
with the target region GCTTAACAATCAAGCCCGT
[21]. siRNA oligos against the GFP sequence GGCTAC
GTCCAGGAGCGCACC were used as non-silencing
control. To specifically knock down the endogenous
TOP2B without affecting the transfected TOP2B-YFP,
three siRNA oligos targeting the 3-UTR of human
TOP2B mRNA were applied, since the TOP2B-YFP ex-











The mutated sites are highlighted by italic bold letters.frame of TOP2B without 3-UTR. The target sequences
for 3-UTR region were as follows: siRNA1: GAAATGT
CACGTACTGTCTGA; siRNA2: ACTGTCTGATTGGC
TTGTAGA; siRNA3: GCTTGTAGAATTGTTATAGAC.
For H9C2 cells, the target sequence of siRNA to knock
down rat Top2b was: GAACAAAGCTGGTGTATCA.
siRNA oligos were transfected at the final concentration
of 50 nM using the jetPRIMETM transfection reagent
(Polyplus Transfection SA, Illkirch, France) according to
the specifications of the manufacturer.Site-directed mutagenesis
The bicistronic vector expressing human TOP2B fused
with enhanced yellow fluorescent protein (YFP) at the
C-terminal has been described previously [22]. Single
amino acid substitution was introduced into this vector
with the site-directed mutagenesis Kit (QuikChange,
Stratagene). Primers for individual TOP2B mutants are
shown in Table 1. The mutated sites are highlighted by
italic bold letters. PCR conditions for mutagenesis were
according to the manufacturer’s instructions. The intro-
duction of the desired and the absence of off-target mu-
tations was verified by sequencing.RNA-Seq data analysis
The raw RNA-Seq data obtained from diverse human
or mouse organs were downloaded in Fastq format from
Gene Expression Omnibus (GEO) in NCBI (accession
number GSE30352) [23]. Original reads were mapped
against human (version GRCh37/hg19) or mouse (version
NCBI37/mm9) genome with TopHat using gene annota-
tion file as the reference for alignment [24]. The genomic
sequence data and gene annotation files were downloaded
from UCSC (http://genome.ucsc.edu/). Mapped reads
were assembled with the program Cufflinks [24] and the
expression levels of individual transcripts were calculated
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All experiments were repeated at least three times. Data
were expressed as mean ± SE and analyzed with the two-
tailed Student’s t-test or one-way ANOVA. P <0.05 was
considered statistically significant.
Results
DRZ depletes cardiac TOP2B protein both in vitro in and
vivo
Western blot analysis of mouse heart homogenates re-
vealed a single band with molecular weight correspond-
ing to Top2b (time 0 h, Figure 1A). This was in
agreement with TOP2B/Top2b mRNA transcripts ac-
counting for >95% of combined TOP2A and TOP2B
transcripts in human or mouse hearts (Figure 1B). To
investigate DRZ effects on Top2b protein expression
in vivo, B6 mice were injected with 200 mg/kg DRZ
and heart tissues were removed 6, 24 or 48 h later for
Western blot analysis. DRZ treatment clearly depressed
Top2b protein expression 6 h after injection, with par-
tial recovery observed at 48 h (Figure 1A). The deple-
tion of Top2b was observed also when DRZ was
followed 30 min later by 20 mg/kg DOX given i.p., which
modelled the recommended time-course of combining
anthracyclines with DRZ in humans (Figure 1C).Figure 1 Cardiac expression of TOP2 isoforms and its response to DR
with 200 mg/kg DRZ. Whole hearts were removed 6, 24 or 48 h after injection
and Top2b under conditions permitting the resolving of these isoforms in H9
levels in different human or mouse organs derived from online available RNA
heart tissues from B6 mice injected i.p. with 200 mg/kg DRZ and/or 20 mg/kg
later for Western blot analysis using an antibody against Top2a and Top2b.These in vivo data differed from the reported expression
of both Top2 isoforms in the cardiomyocyte-derived
H9C2, with DRZ selectively depleting Top2b [15]. We
therefore assessed Top2 levels as a function of H9C2 dif-
ferentiation from fibroblast-like cells to multinucleated
myotubes, which form only after >10 days of culturing
(Figure 2A). Undifferentiated cells expressed both Top2
isoforms (day 2, Figure 2B). The differentiation was ac-
companied by pronounced decrease of Top2a protein
expression and by modest increase of Top2b (Figure 2B).
DRZ and the likewise Top2-binding analogue ICRF-193
depleted Top2b from differentiated H9C2 cells, in con-
trast to the non-binding [25] analogue ICRF-161
(Figure 2C). DRZ, but not ICRF-161 reduced the accu-
mulation of DOX-induced DSB (Figure 2D). These
results were suggestive of DRZ capable of reducing
DOX-induced DSB in cardiac cells via depletion of the
DOX target Top2b, the predominant cardiac Top2
isoform.
The protective effect of DRZ is mediated by the TOP2B
bisdioxopiperazine binding site
To provide a more direct proof of Top2b involvement in
the protective effect of DRZ, we manipulated this en-
zyme’s level. In H9C2 cells, Top2b depletion by meansZ. (A) Top2a/b Western blot of heart tissues from B6 mice injected i.p.
. Western blot was performed with an antibody detecting both Top2a
C2 cells (the leftmost lane). (B) TOP2A and TOP2B mRNA expression
-Seq data (NCBI, GEO accession number GSE30352). (C) Western blot of
DOX, DRZ was given 30 min before DOX. Hearts were removed 24 h
Figure 2 The expression of Top2 isoforms in differentiated cardiomyocytes and their responses to DRZ. (A) Differentiation of H9C2 cells
into myotubes after 3 and 10 days of culturing assessed by light microscopy. Magnification: 10 fold. (B) Western blot analysis of Top2a and Top2b
expression in H9C2 cells during the first 14 days of culturing. (C) The effect of 24 h incubation with DRZ and its analogues ICRF-161 and ICRF-193
(100 μM each) on Top2 expression in H9C2 cells. B and C are Western blots using antibody reacting with both Top2a and Top2b. In B, band densities
of either isoform were divided through those of the time point-matching internal standard β-tubulin and plotted with day 2 Top2/β-tubulin ratio taken
as 100%. (D) The effect of co-treatment with 100 μM DRZ or with its analogue ICRF-161 on DSB γ-H2AX protein levels induced by 1 μM DOX (24 h).
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induced DNA damage (Figure 3B) in a similar way as
did DRZ (Figure 2D). Top2b knockdown by siRNA was
less protective against DSB by 1 μM DOX, consistent
with non-enzyme mediated DSB formation by high con-
centration of DOX [14]. Nevertheless, the reduction of
Top2 still may have been an accompanying rather than
causative event in the prevention of DOX-induced DSB.
To establish a causative link, we took advantage of the
previously identified TOP2A variants which confer re-
sistance against DRZ. We focused on five of those vari-
ants in the N-terminal domain of Top2A, which is
responsible for binding DRZ and other bisdioxopipera-
zines [26]. Wild-type residues of all five Top2A variants
i.e. T49I [27], Y50F [27], R162Q [28], Y165S [29] and
L169F [30,31], are conserved between human TOP2A
and TOP2B. The corresponding residues of TOP2B were
individually mutated (T65I, Y66F, R178Q, Y181S, and
L185F) by site-directed mutagenesis in a vector ex-
pressing wild-type human TOP2B with YFP fused at the
C-terminus [22]. Plasmids encoding WT or mutated
TOP2B were then transiently transfected into human
fibrosarcoma-derived HTETOP cells. We employed for
this experiment HTETOP cells, as they are easier to trans-
fect and offer the possibility of tetracycline (TET)-mediated
depletion of TOP2A [20]. With the exception of R178Q,all mutants were resistant to DRZ-induced depletion when
compared to WT TOP2B in Western blot using anti-YFP
antibody (Figure 3C, upper panel). This was confirmed by
an anti-TOP2B antibody, which also showed the expected
depletion of the endogenous WT TOP2B following DRZ
exposure (Figure 3C, lower panel).
We then investigated if the four TOP2B mutants re-
sistant to DRZ-induced depletion still exhibit protection
against DOX-induced DSB. To be able to distinguish be-
tween DSB mediated by the transfected TOP2B-YFP and
those mediated by endogenous TOP2A or TOP2B, the
endogenous TOP2A was removed by pre-treatment with
TET and TOP2B was knocked down using siRNA oligos
targeting the 3-UTR (Figure 4A). The protein level of
TOP2B-YFP expressed from transfected plasmids remained
unchanged upon siRNA transfection (Figure 4B) as the
3-UTR of TOP2B is absent from these constructs.
DOX-induced DSB formation was much higher in cells
depleted of endogenous TOP2A and TOP2B and trans-
fected with wild-type or mutated TOP2B-YFP than in
mock-transfected cells. As expected, DRZ attenuated
DOX-induced DSB formation in cell transfected with
wild-type TOP2B. In contrast, this protection was abol-
ished by mutant M181 (Figure 4C, upper panel) and
weakened by mutants M185, M65, and M66 (Figure 4C,
lower panel). The above results were consistent with
Figure 3 The effect of N-terminal TOP2B mutants on DRZ-induced TOP2B depletion. (A) siRNA oligonucleotides against rat Top2b or GFP
(control) were transfected into H9C2 cells and Western blot was performed to detect Top2a/b protein level 48 h after transfection. (B) Western
blot of γ-H2AX in mock-, GFP-siRNA- or TOP2B-siRNA-transfected H9C2 cells incubated with 0.1 or 1 μM DOX for 24 h. siRNA were transfected
24 h before DOX addition. (C) HTETOP cells were transiently transfected with plasmids expressing YFP-tagged wild type (WT) or mutated TOP2B
carrying single amino acid mutation. DRZ (100 μM) was added 24 h later and Western blot was conducted using antibody specific for YFP
(upper panel) or human TOP2B (lower panel) after another 24 h.
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ated by the bisdioxopiperazine binding site of TOP2B.
DRZ may deplete TOP2A in addition to TOP2B
In contrast to post-mitotic cells such as cardiomyocytes,
proliferating cells such as tumor cells express TOP2A or
both isoforms rather than TOP2B alone. As any DRZ
interference with TOP2A could affect the TOP2A-
mediated therapeutic response to anthracyclines [19], we
investigated the effect of DRZ on TOP2A and on DOX-
induced DSB mediated by this isoform.
We previously reported DRZ-induced TOP2A depletion
in HTETOP cells, which was proteasome-independent
and accompanied by TOP2A mRNA reduction [14]. The
depletion most likely required direct TOP2A-DRZ inter-
action, as it was absent from cells treated with the non-
binding DRZ analogue ICRF-161 (Figure 5A). Likewise,
ICRF-161 did not reduce DOX-induced DSB accumula-
tion, in contrast to DRZ and ICRF-193 (Figure 5A).
Does DRZ affect DOX-induced DSB formation medi-
ated by TOP2A? To answer this question we first assessed
the contributions of the individual TOP2 isoforms to
DOX-induced DNA damage. DSB were barely detectable
in DOX-treated HTETOP cells depleted of TOP2B by
means of siRNA and of TOP2A by TET (lanes 11–12 vs.2–3 in Figure 5B). The DSB level was higher in DOX-
treated cells expressing TOP2A but not TOP2B (lanes
11–12 vs. 8–9 Figure 5B). Likewise, DOX-induced DSB
were reduced by TET-mediated TOP2A removal in cells
expressing TOP2B (lanes 5–6 vs. 2–3 in Figure 5B). These
results demonstrated that both TOP2 isoforms mediated
DOX-induced DSB.
We then assessed the effect of DRZ on the DOX-
induced DSB formation mediated by each TOP2 isoform.
The formation of DOX-induced DSB in HTETOP cells
depleted of TOP2A by TET was reduced by DRZ (lanes
8–9 vs. 5–6 in Figure 5C). This was accompanied by
TOP2B depletion and it was consistent with the involve-
ment of TOP2B in DOX-induced DNA damage. The ef-
fect of DRZ on DOX-induced and TOP2A-mediated DSB
was assessed in HTETOP cells depleted of TOB2B by
means of siRNA (Figure 5D). The level of DOX-induced
DSB in these cells was further reduced by DRZ (lanes 6
vs. 3 in Figure 5D), indicating the contribution of TOP2A
to the protective effect.
How general a phenomenon is the DRZ-triggered
TOP2A depletion? DRZ (100 μM, 24 h) reduced the
level of TOP2A protein in fibrosarcoma-derived HT1080
(Figure 6A), but neither in lung cancer-derived NYH cells
(Figure 6B), nor in human embryonic cells HEK293
Figure 4 The effect of N-terminal TOP2B mutants on the DNA-protective effect of DRZ. (A) and (B) HTETOP cells were transfected with
siRNA oligonucleotides targeting 3-UTR region of TOP2B mRNA for 48 h. Cells shown in (B) were transfected 24 h earlier with plasmids expressing
YFP-tagged wild type TOP2B. Both endogenous and YFP-tagged TOP2B protein levels were detected by antibody specific for human TOP2B.
(C) HTETOP cells were transfected with plasmid expressing WT or mutated YFP-tagged TOP2B. Twenty-four hours later 1 μg/ml TET and 50 nM
TOP2B 3-UTR siRNA were added for another 24 h, finally the cells were exposed to 1 μM DOX, 100 μM DRZ alone or in combination (DRZ was
given 30 min before DOX) for further 24 h. γ-H2AX accumulation and TOP2A protein level were determined by Western blot. Φ: untreated cells,
as the positive control for TOP2A detection.
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Top2b in a time – and concentration-dependent manner
from differentiated H9C2 cells, which re-express TOP2A
following the addition of fresh serum (Figure 6D).
Discussion
Our study contributes to the mechanistic understanding
of the prevention of anthracycline-induced heart failure
by DRZ. Simultaneously, it suggests mechanistic explan-
ation for the inconsistent and sometimes contradictory
reports of DRZ impact on anthracycline anticancer ther-
apies. In the light of our data, these effects may be medi-
ated by DRZ-triggered depletion of TOP2B.
The long-held view that cardioprotection involves
iron-chelation by the EDTA-like product of the en-
zymatic DRZ hydrolysis ADR-925 has been recently
questioned. Indeed, ADR-925 does not protect cardio-
myocytes against anthracyclines [7], while prevention
of its generation from DRZ does not abolish the cardi-
oprotective effect [8]. These observations implicate
DRZ itself as the cardioprotective compound. As sev-
eral previous studies demonstrated TOP2B depletion
by DRZ and its analogues [14-16], we first verifiedthese observations and investigated the underlying
mechanism in more detail. We found DRZ capable of
TOP2B depletion in all cell lines tested, including dif-
ferentiated cardiomyocytes. In agreement with cell line
data, we detected transient depletion of Top2b by
DRZ in the mouse heart tissue, which constitutes a
first report of this phenomenon in vivo.
We provide several lines of complementary evidence
for DRZ-mediated TOP2B depletion being protective
against anthracycline-induced DNA damage. The re-
duction of DOX-induced DNA damage by DRZ was as-
sociated with TOP2B depletion and it was similar to
that observed upon TOP2B removal by siRNA. That
this reduction was indeed mediated by the TOP2B re-
moval was evidenced first of all by the differential effect of
DRZ analogues. Thus, the reduction of DOX-induced
DNA damage was conferred by TOP2B-binding and
-depleting (DRZ, ICRF-193), but not by the non-
binding and non-depleting bisdioxopiperazine ICRF-
161. In contrast to DRZ, ICRF-161 is not protective
against DOX-induced heart damage [25]. Taken to-
gether with our experiments, a bisdioxopiperazine’s car-
dioprotective effect seems therefore to be determined
Figure 6 TOP2A protein levels in response to DRZ. 24 h incubation with 100 μM DRZ in HT1080 (A), NYH (B), HEK293 (C), and in
differentiated H9C2 cells. The lower panel of (D) additionally shows the effect of incubation time in H9C2 cells.
Figure 5 The individual contributions of TOP2A and TOP2B to DOX-induced DNA damage and to its prevention by DRZ. (A) HTETOP
cells were treated for 24 h with DRZ, its analogue ICRF-161 or ICRF-193, alone or combined with 1 μM DOX. TOP2B, TOP2A and γ-H2AX protein levels
were determined by Western blot. (B) Western blot of γ-H2AX, TOP2B and TOP2A in mock- or TOP2B siRNA-transfected HTETOP cells incubated with
0.1 or 1 μM DOX for 24 h. TOP2A was depleted from HTETOP cells by 24 h pre-incubation with 1 μg/ml TET, followed by TOP2B siRNA transfection.
DOX was added 24 h later following transfection. (C) and (D) HTETOP cells were pre-treated with 1 μg/ml TET (C) or TOP2B siRNA (D) for 24 h,
followed by 24 h exposure to DOX alone or in combination with 100 μM DRZ. DRZ was administered 30 min before DOX. γ-H2AX, TOP2A and TOP2B
protein levels were determined by Western blot.
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late iron. Indirectly, these results support the emerging
evidence that anthracycline-induced cardiotoxicity is
driven by TOP2B-mediated DNA damage rather than
by oxidative stress [17].
To verify these conclusions mechanistically for the
clinically relevant bisdioxopiperazine DRZ, we took ad-
vantage of the existing TOP2 DRZ resistance mutants.
Strikingly, although not surprisingly, these mutants
localize to the bisdioxopiperazine binding site in the N-
terminal domain of TOP2 [26]. All but one mutant pre-
vented the depletion of TOP2B. Simultaneously, these
mutants reduced the protective effect of DRZ against
DOX-induced DNA damage. This result constitutes
currently the strongest evidence that DRZ prevents
DNA damage by depleting TOP2B, which is mediated
through the bisdioxopiperazine binding site.
Taken together with the protective effect of a genetic
Top2b deletion against DOX-induced cardiotoxicity
[17], our results suggest the following model of DRZ-
mediated cardioprotection. DRZ depletes cardiac TOP2B,
thereby reducing the substrate for DOX poisoning. Subse-
quent administration of an anthracycline results in lower
levels of DNA damage than without DRZ pretreatment, i.
e. in the presence of normal TOP2B levels. The depletion
of TOP2B is transient, which reduces the risk or at least
the duration of any adverse effects of this enzyme’s defi-
ciency. Although we have failed to measure DSB in vivo,
this model is fully consistent with the reducing effect of
DRZ on Top2b levels and Top2b-mediated DSB in cul-
tured rat cardiomyocytes. Moreover, it is consistent with
the observation that DRZ is no longer cardioprotective
when given after anthracyclines [32], i.e. when DNA dam-
age has already occurred.
The depletion of TOP2B by DRZ characterized in this
study may also help to resolve the persisting concern of
this drug’s interference with antitumor efficacy of
anthracyclines. This concern has its seeds in a random-
ized, double-blind study of patients with advanced breast
cancer treated with fluorouracil, DOX, and cyclophos-
phamide with or without DRZ [3]. Although time to
progression and survival were not significantly different,
DRZ-treated patients showed a lower tumor response
rate, in addition to the expected reduction of cardiotoxi-
city. The reduction of the response rate is no longer sta-
tistically significant in the latest update of the pertinent
Cochrane meta-analysis, but a trend remains [33].
Based on the growing evidence of TOP2B depletion
by DRZ and its molecular characterization in the
present study, we would like to argue that DRZ may
lower the response rate by depleting TOP2B. Although
the anti-tumor effects of TOP2 poisons are usually at-
tributed to TOP2A rather than TOP2B, the application
of TOP2A level as a therapeutic predictor has beenunsuccessful [34]. Quite the contrary, breast cancer sur-
vival can be predicted by TOP2B rather than TOP2A ex-
pression level [35]. This could be explained by the TOP2B
expression in >90% of cells in breast tumors. In contrast,
TOP2A expression is restricted to the much smaller sub-
set of proliferating (i.e. Ki67-positive) cells of breast tu-
mors [35]. A predominance of TOP2B in the combined
TOP2A/TOP2B activity has been also described in ovar-
ian tumors [36].
As confirmed in the present study, both TOP2 iso-
forms mediate DOX-induced DNA damage in tumor
cells. DRZ-driven depletion of TOP2B would be ex-
pected to reduce this damage and thereby the elimin-
ation of tumor cells. The DRZ-driven depletion of
TOP2B is apparently transient, which would likely
minimize any long-term effects deleterious to tumor
cell survival. In consequence, DRZ would be expected
to reduce tumor shrinkage, a key component of the
tumor response. These considerations are in agreement
with the reduction of therapy response by DRZ de-
tected in breast cancer patients [3].
Importantly, the reduction of tumor response by DRZ
has been observed when DRZ was applied beginning
with the first therapy course [3]. When given to breast
cancer patients first when they had reached a cumula-
tive DOX dose of 300 mg/m2, DRZ almost doubled the
survival [6]. This effect is more difficult to explain in
mechanistic terms, but it is important to remember
that DRZ has some weak antitumor effects [14]. These
effects could become manifest only when a certain
tumor shrinkage has been achieved. In other words, ini-
tially better tumor shrinkage in the absence of DRZ could
sensitize the tumor to this drug’s anti-tumor effect when
included into later therapy courses. Incidentally, this situ-
ation corresponds to the currently approved application of
DRZ in breast cancer patients.
Finally, we verify and expand the original observation
that DRZ may deplete TOP2A in addition to TOP2B [14].
This effect may be mediated by a mechanism different
from that of TOP2B depletion, as it is independent from
the proteasome activity but accompanied by lower
TOP2A mRNA levels [14]. The depletion of TOP2A is
less ubiquitous in comparison to TOP2B, as it has been
detected only in some cell lines. The discrepancy of
DRZ effects on TOP2A in H9C2 cells in this and a pre-
vious work [15] may have been caused by our longer in-
cubation times and by utilization of differentiated cells
which express lower TOP2A levels. It is tempting to
speculate that TOP2A depletion could account for the
only side-effects of DRZ detected in current meta-
analyses, i.e. low white blood count at nadir and anemia
[33]. Indeed, TOP2A is expressed predominantly in
proliferating compartments such as bone marrow [18,37].
The effects of DRZ on the stability and expression of
Deng et al. BMC Cancer 2014, 14:842 Page 10 of 11
http://www.biomedcentral.com/1471-2407/14/842TOP2 isoforms in normal tissues deserve detailed
investigations.
Conclusions
DRZ may prevent doxorubicin-induced DNA damage
through depleting TOP2A and TOP2B. It prevents
anthracycline-induced heart failure via TOP2B degrad-
ation in heart tissues rather than via iron chelation.
The depletion of TOP2B and TOP2A in tumors may
suggest an explanation for the reported DRZ interfer-
ence with cancer response to anthracyclines.
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